Header Logo

JOANNA YI

TitleAssistant Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
Address1102 BATES
Houston, TX 77030
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA06/2013Pediatric Hematology/Oncology
    University of Minnesota Pediatrics Department, Minneapolis, MN06/2010Pediatrics Residency
    University of Wisconsin-Madison School of Medicine and Public Health, Madison, WIMD05/2007Medicine
    University of Wisconsin-Madison, Madison, WIBS05/2003Pharmacology/Toxicology
    Collapse awards and honors
    2008 - 2008Norma K. C. Ramsey Award of Excellence for the Most Outstanding Resident in Pediatric Heme/Onc/BMT, University of Minnesota Pediatrics Department
    2010 - 2010Susan Vincent Outstanding Resident Teaching Award, University of Minnesota Pediatrics Department
    2012 - 2017Loan Repayment Program, NIH
    2014 - 2014Abstract Achievement Award, American Society of Hematology
    2018 - 2018Methods in Clinical Cancer Research Vail Workshop, AACR/ASCO
    2023 - 2023Star Award for Excellence in Patient Care, Baylor College of Medicine
    2023 - 2023TXCH Faculty Education Award, Texas Children's Cancer and Hematology Centers

    Collapse Overview 
    Collapse overview
    Dr. Joanna Yi is a member of Texas Children's Cancer Center's Developmental Therapeutics and Leukemia Teams. Her translational research focuses on the pre-clinical identification and development of new, targeted small molecules for the treatment of childhood cancers with the purpose of evaluating them in early phase clinical trials. She is especially interested in epigenetic drugs and combining them with other active agents.

    Dr. Yi wants to discover new, less toxic, targeted drugs by combining the translational drug discovery techniques of the Center for Drug Discovery at Baylor College of Medicine, with the clinical developmental therapeutics program of Texas Children’s Cancer and Hematology Centers. In the laboratory, Dr. Yi is working with TCH and BCM investigators in the cancer center to identify and characterize small molecules with clinical promise in challenging pediatric cancers. She also is developing tests of “on-target” effect of these compounds to be used in clinical trials and evaluating the targeted small molecules in combination with other active agents to identify the best combinations to move forwards to clinical trials. Her lab is also studying the transcriptional control of pediatric leukemias to find new, druggable targets.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Williams PM, Patton DR, Coffey BD, Reid JM, Piao J, Alonzo TA, Berg SL, Ramirez NC, Jaju A, Fox E, Takebe N, Tricoli JV, Janeway KA, Parsons DW, Chi SN, Yi JS, Roy-Chowdhuri S, Saguilig L, Mhlanga JC, Hawkins DS, Mooney MM, Seibel NL. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363. PMID: 37228094.
      Citations:    Fields:    
    2. Trabal A, Gibson A, He J, McCall D, Roth M, Nu?ez C, Garcia M, Buzbee M, Toepfer L, Bidikian A, Daver N, Kadia T, Short NJ, Issa GC, Ravandi F, DiNardo CD, Montalban Bravo G, Garces S, Marcogliese A, Paek H, Dreyer Z, Brackett J, Redell M, Yi J, Garcia-Manero G, Konopleva M, Stevens A, Cuglievan B. Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience. Cancers (Basel). 2023 Mar 26; 15(7). PMID: 37046645; PMCID: PMC10093646.
      Citations: 1     
    3. Modukuri RK, Yu Z, Tan Z, Ta HM, Ucisik MN, Jin Z, Anglin JL, Sharma KL, Nyshadham P, Li F, Riehle K, Faver JC, Duong K, Nagarajan S, Simmons N, Palmer SS, Teng M, Young DW, Yi JS, Kim C, Matzuk MM. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections. Proc Natl Acad Sci U S A. 2022 05 31; 119(22):e2122506119. PMID: 35622893; PMCID: PMC9295786.
      Citations:    Fields:    Translation:HumansCells
    4. Yi JS, Chambers TM, Getz KD, Miller TP, Burrows E, Daves MH, Lupo PJ, Scheurer ME, Aplenc R, Rabin KR, Gramatges MM. A report from the Leukemia Electronic Abstraction of Records Network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment. Haematologica. 2022 05 01; 107(5):1185-1188. PMID: 35081687; PMCID: PMC9052928.
      Citations:    Fields:    Translation:Humans
    5. Sharma S, Hourigan B, Patel Z, Rosenfeld JA, Chan KM, Wangler MF, Yi JS, Lehman A, CAUSES Study, Horvath G, Cloos PA, Tan Q. Novel CIC variants identified in individuals with neurodevelopmental phenotypes. Hum Mutat. 2022 07; 43(7):889-899. PMID: 35165976.
      Citations:    Fields:    Translation:Humans
    6. Harada T, Heshmati Y, Perez MW, Xavier Ferrucio J, Ewers J, Hubbell Engler B, Kossenkov A, Ellegast JM, Yi JS, Bowker A, Zhu Q, Eagle K, Liu T, Kai Y, Dempster JM, Kugener G, Wickramasinghe J, Herbert ZT, Li CH, Weinstock DM, Paralkar VR, Nabet B, Lin CY, Dharia NV, Stegmaier K, Orkin SH, Pimkin M, Kalfon J, Vrabic Koren J. A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia. Genes Dev. 2022 03 01; 36(5-6):368-389. PMID: 35301220; PMCID: PMC8973843.
      Citations:    Fields:    Translation:Humans
    7. Eagle K, Jiang Y, Shi X, Li M, Obholzer NP, Hu T, Perez MW, Kitano A, Yi JS, Lin CY, Nakada D, Koren JV. An oncogenic enhancer encodes selective selenium dependency in AML. Cell Stem Cell. 2022 03 03; 29(3):386-399.e7. PMID: 35108519; PMCID: PMC8903199.
      Citations:    Fields:    Translation:HumansAnimalsCells
    8. O'Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, Xu X, Yi JS, Harris AC, Brown PA, Borowitz MJ, Militano O, Kairalla J, Devidas M, Raetz EA, Gore L, Loh ML. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. J Clin Oncol. 2022 03 20; 40(9):956-967. PMID: 35007127; PMCID: PMC8937013.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    9. Perez MW, Sias-Garcia O, Daramola A, Wei H, Terrell M, Rashid R, Park WD, Duong K, Horton TM, Li F, Cherayil N, Koren JV, Gant VU, Junco JJ, Curry CV, Stevens AM, Lin CY, Yi JS. Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency. Blood Adv. 2021 12 14; 5(23):4864-4876. PMID: 34543389; PMCID: PMC9153032.
      Citations: 1     Fields:    Translation:HumansAnimals
    10. McCall D, Roth M, Mahadeo KM, Toepfer L, Nunez C, Short NJ, Daver N, Kadia TM, DiNardo C, Yi JS, Cuglievan B. Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Adv. 2021 12 14; 5(23):5215-5219. PMID: 34592761; PMCID: PMC9153013.
      Citations: 1     Fields:    Translation:Humans
    11. Yi JS, Sias-Garcia O, Nasholm N, Hu X, Iniguez AB, Hall MD, Davis M, Guha R, Moreno-Smith M, Barbieri E, Duong K, Koach J, Qi J, Bradner JE, Stegmaier K, Weiss WA, Gustafson WC. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia. 2021 06; 23(6):624-633. PMID: 34107377; PMCID: PMC8192452.
      Citations:    Fields:    Translation:HumansAnimalsCells
    12. Arabzade A, Zhao Y, Varadharajan S, Chen HC, Jessa S, Rivas B, Stuckert AJ, Solis M, Kardian A, Tlais D, Golbourn BJ, Stanton AJ, Chan YS, Olson C, Karlin KL, Kong K, Kupp R, Hu B, Injac SG, Ngo M, Wang PR, Sahm F, Kawauchi D, Pfister SM, Lin CY, Hodges HC, Singh I, Westbrook TF, Chintagumpala MM, Blaney SM, Parsons DW, Pajtler KW, Agnihotri S, Gilbertson RJ, Yi J, Jabado N, Kleinman CL, Bertrand KC, Deneen B, Mack SC, De Le?n LA. ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. Cancer Discov. 2021 09; 11(9):2200-2215. PMID: 33741710; PMCID: PMC8418998.
      Citations: 18     Fields:    Translation:Animals
    13. Pearson AD, DuBois SG, Buenger V, Kieran M, Stegmaier K, Bandopadhayay P, Bennett K, Bourdeaut F, Brown PA, Chesler L, Clymer J, Fox E, French CA, Germovsek E, Giles FJ, Bender JG, Hattersley MM, Ludwinski D, Luptakova K, Maris J, McDonough J, Nikolova Z, Smith M, Tsiatis AC, Vibhakar R, Weiner S, Yi JS, Zheng F, Vassal G. Bromodomain and extra-terminal?inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. Eur J Cancer. 2021 03; 146:115-124. PMID: 33601323.
      Citations: 3     Fields:    Translation:Humans
    14. Chen Z, Zhao Y, Yu Y, Pang JC, Woodfield SE, Tao L, Guan S, Zhang H, Bieerkehazhi S, Shi Y, Patel R, Vasudevan SA, Yi JS, Muscal JA, Xu GT, Yang J. Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo. Oncotarget. 2017 Nov 28; 8(61):104090-104103. PMID: 29262623; PMCID: PMC5732789.
      Citations: 12     Fields:    
    15. Bieerkehazhi S, Chen Z, Zhao Y, Yu Y, Zhang H, Vasudevan SA, Woodfield SE, Tao L, Yi JS, Muscal JA, Pang JC, Guan S, Zhang H, Nuchtern JG, Li H, Li H, Yang J. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling. Oncotarget. 2017 Jan 03; 8(1):1469-1480. PMID: 27903968; PMCID: PMC5352070.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    16. Lu J, Guan S, Zhao Y, Yu Y, Wang Y, Shi Y, Mao X, Yang KL, Sun W, Xu X, Yi JS, Yang T, Yang J, Nuchtern JG. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma. Oncotarget. 2016 Dec 13; 7(50):82757-82769. PMID: 27764791; PMCID: PMC5347730.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    17. Yi JS, Kamihara J, Kesselheim JC, Davies K, van Hoff J, Silverman LB, Mullen EA. Synchronous occurrence of acute lymphoblastic leukemia and wilms tumor in two patients: underlying etiology and combined treatment plan. Pediatr Blood Cancer. 2017 05; 64(5). PMID: 27862952.
      Citations:    Fields:    Translation:Humans
    18. Chen Z, Wang Z, Pang JC, Yu Y, Bieerkehazhi S, Lu J, Hu T, Zhao Y, Xu X, Zhang H, Yi JS, Liu S, Yang J. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. Sci Rep. 2016 07 05; 6:29090. PMID: 27378523; PMCID: PMC4932496.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    19. Green AL, Yi J, Bezler N, Pikman Y, Obeng EA, O'Neil T, Mersereau R, Morrissey L, Billett AL, Tubman VN. A Prospective Cohort Quality Improvement Study to Reduce the Time to Antibiotics for New Fever in Neutropenic Pediatric Oncology Inpatients. Pediatr Blood Cancer. 2016 Jan; 63(1):112-7. PMID: 26292080.
      Citations: 1     Fields:    Translation:Humans
    20. Dhe-Paganon S, Hadler M, Xu X, Wu L, Armstrong SA, Yi JS, Federation AJ, Qi J, St Pierre R, Varca AC, Marineau JJ, Smith WB, Souza A, Chory EJ, Bradner JE. Structure-guided DOT1L probe optimization by label-free ligand displacement. ACS Chem Biol. 2015 Mar 20; 10(3):667-74. PMID: 25397901; PMCID: PMC4504433.
      Citations: 11     Fields:    Translation:HumansCells
    21. Yi JS, Hall BA, Moertel CL, Fritch Lilla SA. A novel APC gene mutation associated with a severe phenotype in a patient with Turcot syndrome. J Pediatr Hematol Oncol. 2014 Apr; 36(3):e177-9. PMID: 24309598.
      Citations: 1     Fields:    Translation:Humans
    22. Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, Marineau JJ, Qi J, Barsyte-Lovejoy D, Yi J, Marcellus R, Iacob RE, Engen JR, Griffin C, Aman A, Wienholds E, Li F, Pineda J, Estiu G, Shatseva T, Hajian T, Al-Awar R, Dick JE, Vedadi M, Brown PJ, Arrowsmith CH, Bradner JE, Schapira M. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun. 2012; 3:1288. PMID: 23250418.
      Citations: 129     Fields:    Translation:HumansCells
    23. Yi JS, Moertel CL, Baker KS. Homozygous alpha-thalassemia treated with intrauterine transfusions and unrelated donor hematopoietic cell transplantation. J Pediatr. 2009 May; 154(5):766-8. PMID: 19364562.
      Citations: 8     Fields:    Translation:Humans
    24. Serra A, Brozoski D, Simeon T, Yi J, Bastasic J, Franciosi R, Jacobs ER, Forster HV. Serotonin and serotonin receptor expression in the aorta of carotid intact and denervated newborns. Respir Physiol Neurobiol. 2002 Sep 04; 132(3):253-64. PMID: 12208084.
      Citations: 2     Fields:    Translation:Animals
    YI's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (164)
    Explore
    _
    Co-Authors (38)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _